Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimustine + temozolomide
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of two alkylating anticancer drugs used in the treatment of malignant gliomas, particularly glioblastoma. Both drugs induce apoptosis in glioma cells at late times following treatment through activation of the MAPK cascade, as shown by phosphorylation of Jun kinase (JNK) and c-Jun, a main component of AP-1. This leads to upregulation of the pro-apoptotic gene BIM, which is critical for inducing apoptosis. The combination has been studied for its efficacy against recurrent malignant gliomas and temozolomide-resistant glioblastoma models.
- Other names
- Nimustine hydrochloride and temozolomideACNU and TMZ combination
02
Targets
DNA
Beyond the preview
Go deeper on nimustine + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimustine + temozolomide.